Growth Hormone Deficiency (GHD) – Opportunity Assessment and Forecast

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Rapid uptake of long-acting growth hormones (GH) is set to shake up the growth hormone deficiency (GHD) space in the three major markets (3MM): the US, Germany and Japan. These therapies are projected to capture over 90% of market share in this region by 2030 due to their potential to improve patient convenience and compliance. Usage of short-acting GHs will markedly decrease over the forecast period as almost all patients switch to treatment with long-acting GHs. These therapies only require patients to self-inject once per week, as compared to short-acting GHs, which require daily injections.

Fiona Chisholm, Pharma Analyst at GlobalData comments: “Short-acting GHs have remained the standard of care in GHD for decades. However, the need for daily injections is associated with poor treatment compliance and, in turn, leads to suboptimal therapeutic outcomes. By dramatically reducing injection burden for patients, long-acting GHs may improve compliance considerably.”

Growth_Hormone_Deficiency_GDHCOA002

GlobalData’s report highlights four long-acting GHs that are projected to enter the market by 2030: Novo Nordisk’s Sogroya (somapacitan-beco), Ascendis Pharma’s TransCon hGH (lonapegsomatropin), Pfizer and OPKO Biologics’ somatrogon and Hanmi Pharmaceuticals’ efpegsomatropin. TransCon hGH is expected to emerge as the market leader, accounting for approximately 47% of all long-acting GH sales by 2030.

Chisholm continues: “TransCon hGH is likely to perform well commercially due to its innovative design, which releases unmodified GH, and its strong efficacy profile. Additionally, while Sogroya recently gained marketing authorization in the US, EU, and Japan for adult GHD, TransCon hGH will benefit from being the first long-acting GH to be approved in the more lucrative pediatric segment.”

Across the 3MM, the GHD market was valued at $1.08bn in 2020, approximately 71% of which was attributable to US sales. The market is projected to grow at a compound annual growth rate of 3.84% to reach $1.57bn by 2030.

Chisholm adds: “Uptake of long-acting GHs represents the main driver of growth over the forecast period. These drugs are expected to be priced at a premium to the currently marketed products due to their superior dosing regimens.”

Scope

  • Overview of Growth Hormone Deficiency , including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
  • Topline Growth Hormone Deficiency market revenue from 2020-2030. Annual cost of treatment and major pipeline product sales in this forecast period are included.
  • Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting Growth Hormone Deficiency treatment sales in the 3MM.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
  • Analysis of the current and future market competition in the global Growth Hormone Deficiency market. Insightful review of the key industry drivers, constraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Questions Answered

– How will the Growth Hormone Deficiency market landscape in the 3MM (US, German and Japan) change from 2020-2030?

– What are the most promising late-stage pipeline products for Growth Hormone Deficiency?

– How do the clinical and commercial attributes of late-stage pipeline products compare with one another, and against existing treatment options?

– What are the remaining unmet needs in Growth Hormone Deficiency?

– What drivers and barriers will affect Growth Hormone Deficiency treatment sales in the 3MM over the forecast period?

Key Highlights

  • During the 10-year forecast period, there is one major pipeline product on track to launch, driving a forecast growth in the 3MM from $1.08BN in 2020 to $1.57BN in 2030.
  • The long-acting GHs are anticipated to be priced at a small premium to the short-acting GHs due to their superior dosing regimens. Uptake of these drugs is expected to improve treatment rates and treatment adherence.
  • The launch of LUM-201 has the potential to increase treatment rates and treatment adherence among PEM-positive pediatric patients due to the more favorable oral administration route.
  • However, The GHD market is highly regulated in order to prevent GH misuse, examples of which include administering GH in order to improve athletic performance, induce anti-aging effects, or promote growth in healthy unaffected children. While these restrictions are often necessary, the stringent regulations may sometimes hinder the ability of those with legitimate GH requirements to access therapies in a timely manner.

Reasons to Buy

The report will enable you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global Growth Hormone Deficiency market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the retinitis pigmentosa market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Novo Nordisk
Pfizer
Eii Lilly
Merck KGaA/EMD Serono
Genentech/Ipsos
Ferring Pharmaceuticals/JCR pharmaceuticals
Sandor
Ascendis Pharma
OPKO Biologics
Hanmi Pharmaceuticals
Lumos Pharma

Table of Contents

1. Executive Summary

2. Disease Overview

3. Epidemiology

4. Current Treatment Options

5. Unmet Needs and Opportunities

6. R&D Strategies

7. Pipeline Assessment

8. Market Outlook

9. Appendix

10. Contact Us

Frequently asked questions

Growth Hormone Deficiency (GHD) – Opportunity Assessment and Forecast thematic reports
Currency USD
$6,995

Can be used by individual purchaser only

$20,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Growth Hormone Deficiency (GHD) – Opportunity Assessment and Forecast was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Growth Hormone Deficiency (GHD) – Opportunity Assessment and Forecast in real time.

  • Access a live Growth Hormone Deficiency (GHD) – Opportunity Assessment and Forecast dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.